Peptimmune

About:

Peptimmune is a drug company focused on the rare skin disease pemphigus vulgaris.

Top Investors: New Enterprise Associates, Silicon Valley Bank, OrbiMed, Covera Ventures, MPM Capital

Description:

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

Total Funding Amount:

$92.9M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2002-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2008-07-17

IPO Status:

Private

Industries: